Emory Healthcare Successfully Completes Robotic Peripheral Endovascular Procedures using Microbot Medical®’s LIBERTY® Endovascular Robotic System

Rhea-AI Summary

Microbot Medical (Nasdaq: MBOT) announced that Emory Healthcare completed the first robotic Prostatic Artery Embolization (PAE) and the first robotic Y-90 radioembolization mapping using the LIBERTY® Endovascular Robotic System on March 26, 2026. The single-use, FDA-cleared LIBERTY system aims to improve precision, reduce radiation exposure, and expand access to peripheral endovascular care. Microbot began a Limited Market Release in November 2025 and plans a Full Market Release at the Society of Interventional Radiology conference in April 2026 to deepen clinical adoption.

Positive

• First robotic PAE performed at Emory (March 2026)
• First robotic Y-90 mapping for liver cancer performed at Emory
• FDA-cleared single-use peripheral endovascular robotic system
• Limited Market Release started November 2025; Full Release planned April 2026

Negative

• Full commercial launch not scheduled until April 2026, limiting near-term adoption

News Market Reaction – MBOT

+3.56%

14 alerts

+3.56% News Effect

+4.9% Peak in 9 min

+$6M Valuation Impact

$169.91M Market Cap

0.0x Rel. Volume

On the day this news was published, MBOT gained 3.56%, reflecting a moderate positive market reaction. Argus tracked a peak move of +4.9% during that session. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $6M to the company's valuation, bringing the market cap to $169.91M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

BPH prevalence (US): 40 million men Radiation reduction: 92% relative reduction Peripheral procedures: 2.5 million annually +5 more

8 metrics

BPH prevalence (US) 40 million men Published research cited for benign prostatic hyperplasia

Radiation reduction 92% relative reduction ACCESS-PVI study for LIBERTY radiation exposure vs standard

Peripheral procedures 2.5 million annually U.S. peripheral endovascular market size

CEO special bonus $140,000 One-time cash award authorized on February 18, 2026

Shelf expenses $25,000.00 Total listed issuance and distribution expenses on S-3/A

SEC registration fee $404.02 Fee included within shelf-related issuance expenses

CEO option grant 480,000 shares Stock options under 2020 Omnibus Performance Award Plan

CTO option grant 105,000 shares Stock options granted to General Manager and CTO

Market Reality Check

Price: $2.39 Vol: Volume 710,443 is about 0...

low vol

$2.39 Last Close

Volume Volume 710,443 is about 0.41x the 20-day average of 1,712,651, indicating subdued pre-news trading interest. low

Technical Price at $2.53 is slightly below the 200-day MA of $2.57 and about 45.82% below the 52-week high, while sitting 87.41% above the 52-week low.

Peers on Argus

MBOT’s modest 1.2% pre-news gain occurred alongside mixed peer moves: STXS (2.2)...

MBOT’s modest 1.2% pre-news gain occurred alongside mixed peer moves: STXS (2.2), AVR (0.73), INFU (0.31) were up, while KRMD (-0.68) and NYXH (-0.31) were down, suggesting stock-specific drivers rather than a uniform sector rotation.

Historical Context

5 past events · Latest: Mar 24 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 24	Pivotal study publication	Positive	-0.8%	ACCESS-PVI pivotal study on LIBERTY published in leading medical journal.
Mar 17	Conference participation	Positive	+1.1%	Roth Conference appearance to discuss LIBERTY commercialization and full launch plans.
Mar 10	Conference participation	Positive	+2.9%	Oppenheimer MedTech conference presentation on LIBERTY experience and growth drivers.
Mar 4	Radiation safety positioning	Positive	+2.5%	LIBERTY positioned as solution following AMA radiation protection policy adoption.
Mar 3	Operations update	Positive	-3.6%	Company confirmed operational stability and U.S. inventory amid geopolitical events.

Pattern Detected

Recent LIBERTY-focused announcements are generally positive and often see modestly positive or mixed price reactions, with occasional divergence even on favorable operational news.

Recent Company History

Over March 2026, Microbot’s news flow has centered on commercialization and validation of the LIBERTY Endovascular Robotic System. Events include confirmation of operational stability amid geopolitical tension, alignment with AMA radiation-safety policy citing a 92% radiation reduction, multiple conference participations, and publication of the ACCESS-PVI pivotal study. Several of these updates led to modest gains, though some positive items saw slight negative reactions. Today’s Emory adoption news extends this commercialization narrative by highlighting real-world, multi-indication peripheral endovascular use ahead of the planned full market release in April 2026.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2025-10-28

The company has an active S-3/A shelf registration filed on 2025-10-28, with amendment language addressing automatic effectiveness under Section 8(a). The filing lists issuance and distribution expenses but does not modify the prospectus terms, and prior prospectus supplements show the shelf has been used via two Form 424B3 filings in November 2025.

Market Pulse Summary

This announcement highlights Emory Healthcare’s successful use of LIBERTY for robotic Prostatic Arte...

Analysis

This announcement highlights Emory Healthcare’s successful use of LIBERTY for robotic Prostatic Artery Embolization in BPH and Y-90 mapping for liver cancer, underscoring multi-indication adoption in peripheral endovascular care. It builds on prior milestones such as FDA clearance, ACCESS-PVI publication, and limited market release ahead of a full launch in April 2026. Investors may focus on procedure breadth, workflow benefits, and the large U.S. market of about 2.5 million peripheral endovascular procedures when evaluating LIBERTY’s commercialization trajectory.

Key Terms

prostatic artery embolization, benign prostatic hyperplasia, y-90 radioembolization, endovascular, +3 more

7 terms

prostatic artery embolization medical

"World’s first robotic Prostatic Artery Embolization (PAE) for Benign Prostatic Hyperplasia"

Prostatic artery embolization is a minimally invasive procedure that reduces blood flow to parts of the prostate by selectively blocking the small arteries that feed it, causing the enlarged tissue to shrink. For investors, it matters because it represents a non-surgical alternative for treating urinary symptoms from prostate enlargement, affecting demand for medical devices, imaging equipment, specialist services, and reimbursement decisions in the urology and interventional radiology markets.

benign prostatic hyperplasia medical

"World’s first robotic Prostatic Artery Embolization (PAE) for Benign Prostatic Hyperplasia (BPH)"

Benign prostatic hyperplasia is a noncancerous enlargement of the prostate gland that can squeeze the urethra and cause urinary symptoms like weak stream, urgency, and incomplete emptying; think of it as a garden hose being pinched so water flow slows. It matters to investors because it creates steady demand for medications, medical devices and procedures, regulatory approvals, and insurance coverage decisions—factors that can drive revenue and growth in healthcare companies serving an aging population.

y-90 radioembolization medical

"robotic Y-90 radioembolization mapping for liver cancer are among the robotic cases"

Y-90 radioembolization is a medical procedure that delivers tiny beads carrying the radioactive atom yttrium-90 directly into blood vessels feeding liver tumors, where they lodge and emit focused radiation that shrinks or destroys cancer cells. For investors, it matters because adoption, clinical results, device makers, and reimbursement shape revenue potential and competitive dynamics in the market for liver cancer treatments—think of it as a targeted missile system for tumors rather than broad-area radiation.

endovascular medical

"peripheral endovascular procedures — minimally invasive treatments for certain vascular conditions"

Endovascular describes medical procedures performed inside blood vessels using thin tubes, wires, and implantable devices guided by imaging—like repairing a broken pipe from the inside rather than opening the wall. It matters to investors because these less-invasive techniques can shorten hospital stays, lower complication rates and create demand for specialized devices and imaging equipment, so changes in adoption, regulation or reimbursement can materially affect healthcare company revenues and margins.

yttrium-90 medical

"tiny beads containing the radioactive isotope yttrium-90 are injected inside the blood vessels"

Yttrium-90 is a radioactive form of the element yttrium used in medicine to deliver focused radiation directly to tumors, often carried on tiny beads or attached to drug molecules so the radiation concentrates in a specific spot rather than the whole body. Investors care because manufacturing capacity, clinical trial outcomes, regulatory approvals, and reimbursement determine commercial sales and margins for companies that make or use these therapies—like owning a key component in a high-demand device.

radioembolization medical

"first robotic Yttrium-90 or Y-90 radioembolization mapping for liver cancer at Emory"

A targeted cancer treatment that delivers tiny radioactive beads through the blood vessels directly into a tumor, where they lodge and emit radiation to kill cancer cells while sparing most healthy tissue; think of it as sending tiny mail carriers that drop off a focused dose only at the tumor site. Investors care because clinical trial results, regulatory approvals, device or therapy adoption, and reimbursement determine market size, revenue potential and regulatory or safety risk for companies involved.

peripheral endovascular procedures medical

"only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures"

Minimally invasive treatments that repair or open narrowed, blocked or damaged blood vessels outside the heart and brain by threading small tools through the vessel—think of fixing a clogged pipe from the inside using balloons, tiny cutters or scaffolds. Investors care because these procedures drive sales for medical devices, hospital revenue and recurring consumables, and their growth depends on aging populations, reimbursement rules and regulatory approvals that affect company earnings and adoption rates.

AI-generated analysis. Not financial advice.

World’s first robotic Prostatic Artery Embolization (PAE) for Benign Prostatic Hyperplasia (BPH) and robotic Y-90 radioembolization mapping for liver cancer are among the robotic cases performed using the LIBERTY System, demonstrating system adoption across multiple case types

ATLANTA and HINGHAM, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Emory Healthcare has successfully completed robotic peripheral endovascular procedures — minimally invasive treatments for certain vascular conditions — using Microbot Medical’s (Nasdaq: MBOT) LIBERTY^® Endovascular Robotic System. Microbot believes that the application of the single-use robotic system can expand patient access to high-quality care. Emory interventional radiologists have now demonstrated successful use of the LIBERTY System on benign prostatic hyperplasia (BPH, commonly known as enlarged prostate), as well as liver cancer.

With the LIBERTY System, Emory’s physicians performed the first robotic prostate artery embolization or (PAE), a minimally invasive, image-guided outpatient procedure to treat BPH. Published research has shown that BPH affects approximately 40 million men in the U.S.

“I’m excited to be part of the first team performing the robotic PAE with the LIBERTY system at Emory,” says Zachary L. Bercu, MD, an interventional radiologist with Emory Healthcare and professor in the Division of Interventional Radiology and Image-Guided Medicine at Emory University School of Medicine. “Using the new system for PAE assists in navigating and handling challenging anatomy with precision. I believe that it represents a significant advancement in how interventional radiologists will approach prostate artery embolization.”

Bercu and a team of specialists also completed the first robotic Yttrium-90 or Y-90 radioembolization mapping for liver cancer at Emory—using the same hand-held robotic system. “The endovascular robotic procedure allows specialists to develop personalized care for liver cancer, steering precisely to the target to deliver a nuanced treatment for each patient,” says Bercu.

“With a sizeable patient population, we believe that LIBERTY can establish endovascular robotic navigation as the standard of care for PAE in patients with enlarged prostates, mirroring how robotic-assisted prostatectomy became the dominant surgical approach for prostate cancer,” says Harel Gadot, Microbot Medical Chairman, CEO & President. “The successful completion of LIBERTY’s cases at Emory reinforces our confidence in the innovation and benefits it can bring to clinicians, patients and procedural workflow.”

Robotic Prostate Artery Embolization or (PAE) for BPH
PAE works to shrink the prostate by blocking its blood supply, improving lower urinary tract symptoms. Using the LIBERTY^® Endovascular Robotic System for PAE, it has been shown to improve efficiency to reach the treatment site inside the blood vessels, because of its allowance of fine motor control.

Y-90 for liver cancer

Precision mapping using the LIBERTY System assists clinicians to visualize the blood vessel in advance of the treatment. Once mapping is completed, tiny beads containing the radioactive isotope yttrium-90 are injected inside the blood vessels that feed a tumor, wedging in blood vessels supplying the cancer cells and delivering a high dose of radiation to the tumor while sparing normal tissue.

The LIBERTY System is the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, and is designed for precise vascular navigation while aiming to reduce radiation exposure and physical strain and improve procedure efficiency.

Microbot Medical commenced the Limited Market Release of the LIBERTY system in November 2025 and plans for a Full Market Release at the Society of Interventional Radiology conference in April 2026, allowing the Company to showcase LIBERTY with the goal to deepen market adoption.

About Emory Healthcare

Emory Healthcare, with 29,500 employees and 11 hospitals, is the most comprehensive academic health system in Georgia. System-wide, it has 3,028 licensed patient beds, more than 3,800 physicians practicing in more than 70 specialties, serving metro Atlanta and Georgia. It also provides services to greater Georgia through a joint venture at St. Francis–Emory Healthcare in Columbus, six regional affiliate hospitals and its clinically integrated physician network.

About Microbot Medical

Microbot Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Microbot’s LIBERTY^® Endovascular Robotic System is the world’s first FDA cleared single-use, remotely operated robotic solution designed for precision, efficiency and safety. Backed by a strong intellectual property portfolio and a commitment to innovation, Microbot is driving the future of endovascular care.

Learn more at www.microbotmedical.com and connect on LinkedIn and X.

Microbot Medical’s Safe Harbor

Statements to future financial and/or operating results, future adoption of products, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “contemplates,” “continues,” “could,” “forecasts,” “intends,” “may,” “might,” “possible,” “potential,” “predicts,” “projects,” “should,” “would,” “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the commercialization of the LIBERTY^® Endovascular Robotic System, and in the development of future versions of or applications for the system, uncertainty in the results of regulatory pathways and regulatory approvals, uncertainty resulting from political, social and geopolitical conditions, particularly any changes in personnel or processes or procedures at the FDA and announcements of tariffs on imports into the U.S., disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical^® can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical^® disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Contacts:
IR@microbotmedical.com
Media@microbotmedical.com

Janet Christenbury, Emory Healthcare

janet.christenbury@emoryhealthcare.org

FAQ

What did Microbot (MBOT) announce about robotic PAE at Emory on March 26, 2026?

Emory completed the first robotic Prostatic Artery Embolization (PAE) using LIBERTY, demonstrating feasibility for BPH treatment. According to Microbot, the procedure showed the system’s fine motor control may improve navigation and procedural efficiency in challenging anatomy.

How did Microbot (MBOT) use LIBERTY for Y-90 radioembolization mapping at Emory?

Emory performed the first robotic Y-90 mapping with LIBERTY to assist pre-treatment vascular visualization and planning. According to Microbot, precise robotic navigation helped target vessels for personalized liver cancer therapy prior to microsphere delivery.

Is the LIBERTY system FDA-cleared and what is its market status for MBOT as of March 26, 2026?

The LIBERTY System is FDA-cleared as a single-use, remotely operated peripheral endovascular robotic system. According to Microbot, Limited Market Release began November 2025 with a Full Market Release planned for April 2026 at SIR.

What potential clinical benefits does LIBERTY offer for endovascular procedures mentioned by MBOT?

LIBERTY aims to improve vascular navigation precision, reduce radiation exposure, and lessen operator strain during procedures. According to Microbot, these features may improve efficiency reaching treatment sites and support complex interventions like PAE and Y-90 mapping.

When will Microbot (MBOT) showcase LIBERTY widely to drive market adoption?

Microbot plans a Full Market Release and broader showcase of LIBERTY at the Society of Interventional Radiology conference in April 2026. According to Microbot, the timing targets deeper clinical adoption and visibility among interventional specialists.